Streetbeat News

RGC

Regencell Bioscience Holdings Limited

https://www.regencellbioscience.com

Industry

Drug Manufacturers - Specialty & Generic

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Open

5.89

Mkt cap

74M

Volume

24K

High

6.08

P/E Ratio

-17.12

52-wk high

32.44

Low

5.60

Div yield

N/A

52-wk low

3.03

RGC Resources, Inc. reported an increase in earnings for the fiscal year 2024, driven by its investment in the Mountain Valley Pipeline and despite lower natural gas costs and higher interest expenses.

Portfolio Pulse from

November 13, 2024 | 10:15 pm

Several healthcare stocks experienced significant price movements during Monday's intraday session. Notable gainers included Healthcare Triangle, Monte Rosa Therapeutics, and Evoke Pharma, while Sonnet BioTherapeutics and Koninklijke Philips were among the losers. The movements were influenced by various factors, including earnings reports.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 4:30 pm

Regencell Bioscience shares are experiencing an upward trend following the announcement of a year-over-year increase in FY24 EPS results.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 4:30 pm

Regencell Bioscience reported a quarterly loss of $(0.33) per share, an improvement from the $(0.45) per share loss in the same period last year, marking a 26.67% increase.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 3:18 pm

The article reports on the intraday movements of several healthcare stocks. Notable gainers include NewGenIvf Group, Universe Pharmaceuticals, and Pacific Biosciences, while Perspective Therapeutics, Protagenic Therapeutics, and Regencell Bioscience are among the losers.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 4:31 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Notable gainers included NewGenIvf Group (NIVF) with a 71.8% increase, Conduit Pharmaceuticals (CDT) up by 40.77%, and Kindly MD (KDLY) rising by 17.76%. On the losing side, Carmell (CTCX) fell by 12.4%, Jin Medical International (ZJYL) decreased by 8.74%, and LakeShore Biopharma (LSB) dropped by 8.14%.

Portfolio Pulse from Benzinga Insights

October 11, 2024 | 12:07 pm

In Thursday's after-market session, several health care stocks experienced significant price movements. Notable gainers included NewGenIvf Group (NIVF) with a 58.1% increase, and SunLink Health Systems (SSY) with a 17.13% rise. On the losing side, Klotho Neurosciences (KLTO) fell by 6.5%, and Humana (HUM) declined by 4.76%.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 8:31 pm

Several healthcare stocks experienced significant price movements during Thursday's intraday session. Notable gainers included TransCode Therapeutics, Vaccinex, and NexGel, while Gritstone Bio and 10x Genomics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 4:31 pm

Several healthcare stocks experienced significant price movements during Tuesday's intraday session. Ontrak, Regional Health Props, Bio-Path Holdings, Portage Biotech, Regencell Bioscience, and Shattuck Labs saw notable gains, while Vincerx Pharma, TransCode Therapeutics, LogicMark, Galecto, Beyond Air, and Instil Bio experienced declines.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:31 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. Scholar Rock Holding (SRRK) saw a massive increase of 198.1%, while Trevena (TRVN) experienced a sharp decline of 45.5%. Other notable gainers include LogicMark (LGMK) and Biohaven (BHVN), while Entero Therapeutics (ENTO) and Onconetix (ONCO) were among the losers.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 12:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.